Drug Approval | December 28, 2021
Optimus Pharma to manufacture and market molnupiravir
The company has developed the API in house at its R&D center in Hyderabad
The company has developed the API in house at its R&D center in Hyderabad
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
The company has strong product launches both in India and overseas
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
